Skip to content
Homepage
Author:
Vor Biopharma
Posted Date:
July 7, 2026
Vor Bio Appoints David Zaccardelli to Board of Directors
Vor Biopharma
July 7, 2026
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Biopharma
July 2, 2026
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
Vor Biopharma
June 8, 2026
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
Vor Biopharma
June 8, 2026
